What Is Cenderitide? Definition and What Research Reports

Cenderitide (also written CD-NP) is an investigational, laboratory-designed peptide belonging to the natriuretic peptide family. It is a chimeric molecule: the ring structure of human C-type natriuretic peptide (CNP) was joined to the C-terminal amino acid tail of Dendroaspis natriuretic peptide (DNP), a peptide originally identified in the venom of the green mamba snake. The resulting hybrid was intended to engage more than one natriuretic peptide receptor simultaneously and to raise intracellular cyclic guanosine monophosphate (cGMP), the second messenger through which natriuretic peptides act. A 2019 review in International Journal of Cardiology described cenderitide as a novel first-in-class designer natriuretic peptide developed for heart failure (PMID 29941213). This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about any medical condition or treatment.

Molecular Class and Origin

Natriuretic peptides are a family of ring-shaped hormones that includes atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). They signal through membrane-bound (particulate) guanylyl cyclase receptors — principally GC-A, which responds to ANP and BNP, and GC-B, which responds to CNP — and receptor activation generates cGMP inside the target cell.

Cenderitide sits in this family but does not occur in nature. It is a designer or chimeric peptide, meaning its sequence was assembled from two different parent peptides rather than isolated from a tissue or gland. Researchers examined the structural features responsible for its activity and characterised cenderitide as a dual particulate guanylyl cyclase receptor agonist with renal-enhancing actions demonstrated both in vivo and ex vivo (PMID 27340557). That dual-receptor design is the defining conceptual feature of the molecule in the published literature: it is described less as a new hormone than as an engineered attempt to combine properties of two existing ones.

How the Term Is Used in Peptide Research

In papers and conference abstracts, "cenderitide" and "CD-NP" are used interchangeably. The term appears in three broad contexts:

• Cardiorenal pharmacology. Studies describing receptor binding, cGMP generation, and effects on kidney and cardiovascular endpoints in animal models and in humans.
• Heart failure therapeutics. Discussions of natriuretic-peptide-based drug development, where cenderitide is cited as a first-in-class example of the designer-peptide strategy (PMID 29941213).
• Biomaterials and local delivery. Engineering work on coatings, films and stents intended to release the peptide at a specific site rather than systemically.

Because cenderitide is a defined research compound rather than a marketed product, the word functions in the literature as a proper name for one specific sequence, not as a category label.

What the Published Literature Reports

Human study in chronic heart failure

The most directly clinical publication is a human study reported in Clinical Pharmacology and Therapeutics in 2018, which evaluated the safety, tolerability and cGMP-activating properties of cenderitide delivered by subcutaneous administration in subjects with stable chronic heart failure (PMID 29226471). In that study, researchers reported that cenderitide administration was associated with activation of cGMP, the intended pharmacodynamic marker of natriuretic peptide receptor signalling (PMID 29226471). The work was framed as an early-phase safety and tolerability evaluation rather than as a test of clinical outcomes such as hospitalisation or survival.

Structure-function and renal actions

Preclinical characterisation examined which parts of the chimeric sequence were required for activity. Researchers reported that cenderitide acted as a dual agonist at particulate guanylyl cyclase receptors and produced renal-enhancing actions in in vivo and ex vivo models (PMID 27340557). This line of work underpins the rationale repeated in review articles: that combining CNP and DNP elements was intended to preserve renal and anti-fibrotic signalling while limiting the blood-pressure-lowering profile associated with single-receptor natriuretic peptides (PMID 29941213).

Local and device-based delivery

A separate body of work treated cenderitide as a payload for biomaterials rather than as a systemic infusion. A 2014 study in the Journal of Pharmaceutical Sciences investigated controlled-release platforms for potential local treatment of cardiovascular pathology (PMID 24590596), and a 2013 PLoS One paper described a cenderitide-eluting film developed for potential cardiac patch applications (PMID 23861890).

Stent work proceeded in two reported stages. The in vitro evaluation of a cenderitide-eluting stent was framed by researchers as an antirestenosis and pro-endothelialisation approach (PMID 25223419), and a follow-on in vivo evaluation of the cenderitide-eluting stent was published in Annals of Biomedical Engineering in 2016 (PMID 26178873). These are device and formulation studies; they describe engineering feasibility rather than patient outcomes.

Published research at a glance

Cenderitide Adverse Events: What Studies Report

Tolerability information for cenderitide in people comes chiefly from one publication. The 2018 human study was designed specifically to evaluate safety and tolerability alongside cGMP activation in subjects with stable chronic heart failure (PMID 29226471). Because natriuretic peptides act on vascular tone, blood pressure response is the endpoint most closely monitored in this class, and the 2019 review discussed the class-wide challenge of separating desirable cardiorenal signalling from unwanted haemodynamic effects (PMID 29941213). The device and formulation studies did not evaluate systemic tolerability in humans; the stent and film papers reported engineering and biological feasibility endpoints in laboratory and animal settings (PMID 26178873). Readers should note that a small early-phase evidence base cannot characterise uncommon or long-term adverse events.

Regulatory and Availability Status

Cenderitide is an investigational compound. It is not an approved medicine in the United States or elsewhere, and the published record consists of early-phase clinical and preclinical work rather than completed outcome trials. Peptides in this position are typically handled as research-use-only materials in laboratory settings and are not consumer products. Nothing on this page describes availability, sourcing or personal use.

Related Terms

• CD-NP — the original development name for cenderitide.
• CNP (C-type natriuretic peptide) — the parent peptide contributing the ring structure.
• DNP (Dendroaspis natriuretic peptide) — the snake-venom-derived peptide contributing the C-terminal tail.
• Particulate guanylyl cyclase (GC-A, GC-B) — the membrane receptors that generate cGMP when natriuretic peptides bind; cenderitide was characterised as a dual agonist at these receptors (PMID 27340557).
• cGMP — the intracellular second messenger measured as a pharmacodynamic marker in the human study (PMID 29226471).

References

• Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide (International Journal of Cardiology, 2019)
• A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure (Clinical Pharmacology and Therapeutics, 2018)
• Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions (European Heart Journal. Cardiovascular Pharmacotherapy, 2016)
• In vivo Evaluation of Cenderitide-Eluting Stent (CES) II (Annals of Biomedical Engineering, 2016)
• In vitro evaluation of cenderitide-eluting stent I — an antirestenosis and proendothelization approach (Journal of Pharmaceutical Sciences, 2014)
• Investigation of cenderitide controlled release platforms for potential local treatment of cardiovascular pathology (Journal of Pharmaceutical Sciences, 2014)
• Cenderitide-eluting film for potential cardiac patch applications (PLoS One, 2013)